Living Donor Lung Transplantation for Pleuroparenchymal Fibroelastosis

We report the first patient with pleuroparenchymal fibroelastosis (PPFE) to undergo living donor bilateral lobar lung transplantation. The patient was diagnosed with secondary PPFE as a late complication of chemotherapy that included high-dose cyclophosphamide for mature B-cell lymphocytic leukemia....

Full description

Saved in:
Bibliographic Details
Published inThe Annals of thoracic surgery Vol. 101; no. 5; pp. 1970 - 1972
Main Authors Hata, Atsushi, MD, Nakajima, Takahiro, MD, PhD, Yoshida, Shigetoshi, MD, PhD, Kinoshita, Taku, MD, Terada, Jiro, MD, PhD, Tatsumi, Koichiro, MD, PhD, Matsumiya, Goro, MD, PhD, Date, Hiroshi, MD, PhD, Yoshino, Ichiro, MD, PhD
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.05.2016
Subjects
Adult
Antineoplastic Agents - adverse effects
Cardiothoracic Surgery
Humans
Leukemia, B-Cell - drug therapy
Living Donors
Lung Transplantation
Male
Pleural Diseases - surgery
Pulmonary Fibrosis - surgery
Surgery
Online AccessGet full text

Cover

More Information
Summary:We report the first patient with pleuroparenchymal fibroelastosis (PPFE) to undergo living donor bilateral lobar lung transplantation. The patient was diagnosed with secondary PPFE as a late complication of chemotherapy that included high-dose cyclophosphamide for mature B-cell lymphocytic leukemia. Although the patient maintained complete remission, dry cough and back pain appeared 8 years after the chemotherapy. He had repeated bilateral pneumothoraces, and his respiratory condition gradually deteriorated because of progressive pleural thickening and parenchymal fibrosis. He underwent living-donor bilateral lobar lung transplantation with an inverse transplant on the left side.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0003-4975
1552-6259
DOI:10.1016/j.athoracsur.2015.07.056